WO2018043733A1 - Method and kit for detecting pathogenic microorganism - Google Patents
Method and kit for detecting pathogenic microorganism Download PDFInfo
- Publication number
- WO2018043733A1 WO2018043733A1 PCT/JP2017/031689 JP2017031689W WO2018043733A1 WO 2018043733 A1 WO2018043733 A1 WO 2018043733A1 JP 2017031689 W JP2017031689 W JP 2017031689W WO 2018043733 A1 WO2018043733 A1 WO 2018043733A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enzyme
- virus
- pathogenic microorganism
- reaction product
- hydrophilic solvent
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
- C12Q2334/20—Coumarin derivatives
- C12Q2334/22—4-Methylumbelliferyl, i.e. beta-methylumbelliferone, 4MU
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a method and kit for detecting pathogenic microorganisms. More specifically, in a minimal volume of hydrophilic solvent coated with a hydrophobic solvent, the pathogenic microorganism is detected by optically detecting the reaction product generated as a result of the reaction by the enzyme on or inside the pathogenic microorganism.
- the present invention relates to a method for performing detection.
- Patent Document 1 a simple influenza virus test kit using immunochromatography has been developed (see Patent Document 1). Since the method using immunochromatography can detect influenza virus within minutes to tens of minutes, it is utilized for diagnosis and treatment of infection.
- Patent Documents 2 and 3 a technique for optically detecting influenza virus based on the reaction between neuraminidase, which is an enzyme of influenza virus, and a chromogenic substrate is known (see Patent Documents 2 and 3).
- the chromogenic substrate include 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuramic acid: 4MU-NANA, see Patent Document 2), 4-alkoxy A derivative of —N-acetylneuraminic acid or 4,7-dialkoxy-N-acetylneuraminic acid (see Patent Document 3) is used.
- 4-methylumbelliferone which is a fluorescent substance
- the neuraminidase enzyme activity value can be calculated based on the amount of 4-methylumbelliferone produced, and the number of influenza virus particles can be quantified based on the enzyme activity value.
- Non-Patent Document 1 discloses a single-molecule enzyme assay using an array of femtoliter-order droplets in which the droplets are covered with oil and directly accessible from the outside. A method is described.
- the main object of the present invention is to provide a technique that can be used to detect viruses such as influenza viruses with high sensitivity.
- the present invention provides the following [1] to [25].
- [1] A method for detecting the pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism, A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed.
- An introduction procedure for introducing a hydrophilic solvent containing the biological sample and a substance serving as a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism into a space between the upper layer portion An encapsulation procedure for introducing a hydrophobic solvent into the space, and forming droplets of the hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism and the substance in the container, A detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet, The method, wherein the hydrophilic solvent has a pH value greater than the acid dissociation constant (pKa) of the reaction product.
- pKa acid dissociation constant
- the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid), and the reaction product is 4-methylumbelliferone [1] or [2].
- the pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [1] or [2], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase and RNA-dependent RNA polymerase.
- the substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine. [1] or [2].
- a method for diagnosing the presence or absence of infection with a pathogenic microorganism A procedure for separating a biological sample from a subject suspected of being infected; A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed.
- the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid) and the reaction product is 4-methylumbelliferone, [6] to [8].
- the pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus Any one of [6] to [8], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase, and RNA-dependent RNA polymerase.
- the substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine. Any one of [6] to [8].
- a method for detecting drug sensitivity of a pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed.
- the hydrophilic solvent has a pH value larger than an acid dissociation constant (pKa) of the reaction product.
- the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid), the reaction product is 4-methylumbelliferone, and the inhibitor is a neuraminidase inhibitor [12] or [13].
- a method of screening for anti-pathogenic microbial agents A plurality of accommodating parts capable of accommodating pathogenic microorganisms are opposed to a lower layer part formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface on which the accommodating part is formed in the lower layer part Introducing a hydrophilic solvent containing the pathogenic microorganism, a substance serving as a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism, and a candidate compound into a space between the upper layer portion and the upper layer portion When, An enclosing procedure for introducing a hydrophobic solvent into the space and forming droplets of a hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism, the substance, and the candidate compound in the container.
- the hydrophilic solvent has a pH value larger than an acid dissociation constant (pKa) of the reaction product.
- the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid), the reaction product is 4-methylumbelliferone, and a neuraminidase inhibitor is screened as the candidate compound [15] or [16].
- a kit for detecting the pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism A space between a lower layer portion in which a plurality of accommodating portions capable of accommodating the pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed
- An array comprising an upper layer portion facing each other, and A substance that is a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism;
- a kit comprising a hydrophobic solvent.
- the pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic). acid), and the reaction product is 4-methylumbelliferone [18].
- the pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, Middle East respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [18] The kit according to [18], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase, and RNA-dependent RNA polymerase.
- the substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine.
- a method of detecting a reaction product by reacting an enzyme with a substance serving as a substrate for a reaction by the enzyme in a hydrophilic solvent in interface with the hydrophobic solvent The method, wherein the hydrophilic solvent has a pH value greater than the acid dissociation constant (pKa) of the reaction product.
- the hydrophilic solvent contains a pathogenic microorganism,
- the enzyme is an enzyme having a substrate cleavage activity present on the surface or inside of the pathogenic microorganism,
- the substance is a chromogenic substrate;
- the method according to [22] wherein a reaction product generated by cleavage of the chromogenic substrate by the enzyme is optically detected.
- the pathogenic microorganism is an influenza virus
- the enzyme is neuraminidase
- the chromogenic substrate is 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-
- the pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [23] The method according to [23], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase and RNA-dependent RNA polymerase.
- the chromogenic substrate is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine.
- the method of [23] which is one or more of the following.
- the method of any of [23] to [26], wherein the hydrophilic solvent comprises a biological sample separated from a subject infected with or suspected of being infected with the pathogenic microorganism.
- pathogenic microorganisms include bacteria and viruses.
- bacteria include, but are not limited to, coliform bacteria, Vibrio parahaemolyticus, Campylobacter, Enterobacter, and Bacillus bacteria.
- virus is not particularly limited, but for example, coronavirus, SARS virus, MARS virus, influenza virus, mump virus, measles virus, nipavirus, canine distemper virus, HIV, hepatitis B virus, HTLV, Ebola virus, type C Examples include hepatitis virus, Lassa virus, hantavirus, rabies virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus.
- the present invention provides a technique that can be used to detect pathogenic microorganisms such as influenza virus with high sensitivity.
- Pathogenic microorganism detection method The pathogenic microorganism detection method according to the present invention is used to detect pathogenic microorganisms in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism. is there.
- the pathogenic microorganism detection method according to the present invention includes the following procedures.
- the biological sample is not particularly limited as long as it is a biological material that can contain pathogenic microorganisms to be detected.
- biological samples include nasal aspirate, nasal swab, throat swab, tracheal swab, saliva, sputum, blood (including whole blood, serum and plasma), urine, cells and tissues, organ extracts, etc. Is mentioned.
- the pathogenic microorganism is not particularly limited as long as it has an enzyme on the surface or inside thereof and generates a reaction product that can be detected optically as a result of the reaction by the enzyme. More specifically, the pathogenic microorganism has an enzyme having a substrate-cleaving activity for a chromogenic substrate on the surface or inside thereof, and the reaction product as a chromophore is liberated by the cleavage of the chromogenic substrate by the enzyme. .
- pathogenic microorganisms have an enzyme on the surface or inside that has an activity of synthesizing a polymer by binding a monomer as a substrate, and a reaction generated as a chromophore with the synthesis of the polymer by the enzyme It may be one that generates a product.
- enzymes on the surface or inside that has an activity of synthesizing a polymer by binding a monomer as a substrate, and a reaction generated as a chromophore with the synthesis of the polymer by the enzyme It may be one that generates a product. Examples of combinations of pathogenic microorganisms and their enzymes include the following.
- the lower layer portion 10 is formed by a plurality of accommodating portions 13 capable of accommodating virus particles separated from each other by a side wall 12 having a hydrophobic upper surface. Further, the upper layer portion 20 faces the surface of the lower layer portion 10 where the accommodating portion 13 is formed.
- a hydrophilic solvent 42 is introduced into the space 30 between the lower layer portion 10 and the upper layer portion 20.
- the hydrophilic solvent 42 may contain virus 2 derived from a biological sample. Further, the hydrophilic solvent 42 includes a substance 3 (hereinafter referred to as “substrate 3”) which is a substrate for a reaction by an enzyme present on the particle surface (or inside) of the virus 2.
- substrate 3 a substance 3
- the hydrophilic solvent 42 can be introduced into the space 30 from a through hole (not shown) formed in at least one of the upper layer part 20 and the lower layer part 10, for example. As shown in the drawing, the hydrophilic solvent 42 introduced into the space 30 flows in a direction parallel to the surface where the lower layer portion 10 and the upper layer portion 20 face each other.
- the hydrophilic solvent 42 has a pH value larger than the acid dissociation constant (pKa) of the reaction product generated from the substrate 3 (details will be described later).
- the substrate 3 may be any substrate that generates a reaction product having optical characteristics different from those before the reaction after the reaction with the enzyme, and a substance whose absorbance or optical rotation changes before and after the reaction, or exhibits fluorescence after the reaction. The substance that becomes is used.
- the substrate 3 will be described in detail later.
- the hydrophilic solvent 42 may contain a buffer substance necessary for optimizing the reaction between the enzyme and the substrate 3. Furthermore, by setting the buffer substance in the hydrophilic solvent 42 to a predetermined concentration or more, the detection of the reaction product can be made more sensitive in the detection procedure (3) (details will be described later).
- MES 2-Morpholinoethanesulfonic acid
- ADA N- (2-Acetamido) iminodiacetic acid
- PIPES Piperazine-1,4-bis (2- ethanesulfonic acid)
- ACES N- (2-Acetamido) -2-aminoethanesulfonic acid
- BES N, N-Bis (2-hydroxyethyl) -2-aminoethanesulfonic acid
- TES N-Tris (hydroxymethyl) methyl- So-called good buffers such as 2-aminoethanesulfonic acid HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid), Tris (tris (hydroxymethyl) aminomethane), DEA (diethanolamine) and the like can be used.
- the hydrophilic solvent 42 may contain a surfactant.
- a surfactant By including a surfactant, the enzyme present in the virus 2 may be exposed on the surface.
- the surfactant by including the surfactant, the hydrophilic solvent 42 tends to be easily introduced into the space 30 and the accommodating portion 13.
- the surfactant is not particularly limited.
- TWEEN 20 (CAS number: 9005-64-5, polyoxyethylene sorbitan monolaurate) and Triton X-100 (CAS number: 9002-93-1, generic name polyethylene glycol mono) -4-octylphenyl ether (n ⁇ 10)) and the like.
- the concentration of the surfactant added to the first solvent 20 is not particularly limited, but is preferably 0.01 to 1%.
- an anionic surfactant an anionic surfactant, a cationic surfactant, a nonionic surfactant, a zwitterionic surfactant, a naturally derived surfactant and the like can be widely used.
- anionic surfactant examples include a carboxylic acid type, a sulfate ester type, a sulfonic acid type, and a phosphate ester type.
- specific examples include sodium dodecyl sulfate, sodium laurate, sodium ⁇ -sulfo fatty acid methyl ester, sodium dodecyl benzene sulfonate, sodium dodecyl ethoxylate sulfate, etc.
- sodium dodecyl benzene sulfonate is used. It is preferable to use it.
- Examples of the cationic surfactant are classified into a quaternary ammonium salt type, an alkylamine type, and a heterocyclic amine type. Specific examples include stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, didecyl dimethyl ammonium chloride, cetyl tripyridinium chloride, dodecyl dimethyl benzyl ammonium chloride, and the like.
- Nonionic surfactants include, for example, polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene mono fatty acid ester, polyoxyethylene sorbitan mono fatty acid ester, sucrose fatty acid ester, polyglycerin fatty acid ester, alkyl polyglycoside , N-methylalkylglucamide and the like.
- amphoteric surfactants include lauryldimethylaminoacetic acid betaine, dodecylaminomethyldimethylsulfopropylbetaine, and 3- (tetradecyldimethylaminio) propane-1-sulfonate, but 3-[(3-colamide Propyl) dimethylammonio] -1-propanesulfonate (CHAPS), 3-[(3-colamidopropyl) dimethylammonio] -2-hydroxy-1-propanesulfonate (CHAPSO) and the like are preferably used.
- lauryldimethylaminoacetic acid betaine dodecylaminomethyldimethylsulfopropylbetaine
- 3- (tetradecyldimethylaminio) propane-1-sulfonate but 3-[(3-colamide Propyl) dimethylammonio] -1-propanesulfonate (CHAPS), 3-[(3-colamidopropyl) dimethylammoni
- lecithin and saponin are preferable, and among the compounds referred to as lecithin, specifically, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, etc. preferable.
- a saponin Kiraya saponin is preferable.
- the virus 2 and the substrate 3 enter the storage unit 13 by this procedure.
- the number of viruses 2 entering one container 13 can be 0 or 1 at the maximum.
- the concentration of the virus 2 is higher in the hydrophilic solvent 42, two or more viruses 2 can be introduced into one container 13.
- the hydrophobic solvent 43 may be any solvent (immiscible solvent) that is difficult to mix with the hydrophilic solvent 42 used in the introduction procedure (1).
- the hydrophobic solvent 43 include at least one selected from the group consisting of saturated hydrocarbons, unsaturated hydrocarbons, aromatic hydrocarbons, silicone oils, perfluorocarbons, halogenated solvents, and hydrophobic ionic liquids. A mixture or the like can be preferably used.
- saturated hydrocarbons include alkanes and cycloalkanes. Examples of alkane include decane and hexadecane. Examples of the unsaturated hydrocarbon include squalene.
- aromatic hydrocarbons include benzene and toluene.
- the perfluorocarbon examples include Fluorinert (registered trademark) FC40 (manufactured by SIGMA).
- the halogen solvent examples include chloroform, methylene chloride, chlorobenzene and the like.
- the hydrophobic ionic liquid refers to an ionic liquid that does not dissociate at least in water, and examples thereof include 1-Butyl-3-methylimidazolium, Hexafluorophosphate.
- An ionic liquid refers to a salt that exists as a liquid at room temperature.
- the hydrophobic solvent 43 may be introduced into the space 30 from a through-hole (not shown) formed in at least one of the upper layer portion 20 and the lower layer portion 10, similarly to the hydrophilic solvent 42. As shown in the drawing, the hydrophobic solvent 43 introduced into the space 30 flows in a direction parallel to the surface where the lower layer portion 10 and the upper layer portion 20 face each other, and the hydrophilic solvent 42 in the space 30 is a hydrophobic solvent. 43 is substituted. As a result, a droplet of the hydrophilic solvent 42 that is covered with the hydrophobic solvent 43 and includes the virus 2 and the substrate 3 is formed in the accommodating portion 13.
- reaction product 4 is present on or inside the particle of virus 2 (the figure shows the case where enzyme 5 is present on the virus surface).
- a reaction product 4 is generated.
- the colored product 4 exhibits optical characteristics different from those of the substrate 3 and exhibits, for example, a shift in absorbance and optical rotation and luminescence (fluorescence).
- the volume of the container 13 (that is, the volume of the droplet of the hydrophilic solvent 42) is not particularly limited, but is, for example, 10 aL to 100 nL, preferably 1 fL to 1 pL.
- Virus 2 is an influenza virus (see Table 1), and 4-methylumbelliferyl- ⁇ -D-neuraminic acid (4-Methylumbelliferyl-N-acetyl- ⁇ -D-neuraminic acid: 4MU-NANA) is used as substrate 3 The case where it is used will be described specifically by way of example.
- Neuraminidase (enzyme 5) is present on the surface of influenza virus particles.
- 4MU-NANA substrate 3
- 4-methylumbelliferone reaction product 4
- 4-Methylumbelliferone is generated as a fluorescent chromophore represented by the following formula, derived from hydrolysis of 4MU-NANA by neuraminidase.
- the substrate 3 is not limited to 4MU-NANA, and any conventionally known one can be used as long as it releases a chromophore that can be detected optically by neuraminic acid hydrolysis by neuraminidase.
- 4MU of the reaction product 4 has a hydroxyl group as shown by the following formula.
- hydrogen is desorbed from the hydroxyl group of 4 MU to bring 4 MU into a charged state, so that the pH value of the hydrophilic solvent 42 is higher than the acid dissociation constant (pKa) of 7.79 of 4 MU. Set larger.
- the 4MU contained in the droplet of the hydrophilic solvent 42 coated with the hydrophobic solvent 43 cannot move to the hydrophobic solvent 43 due to its charge, and as a result It accumulates in a high concentration in the droplets of the hydrophilic solvent 42.
- the pH value of the hydrophilic solvent 42 is smaller than the acid dissociation constant (pKa) of 4 MU, 4 MU has a hydroxyl group, and therefore has no charge or when hydrogen is desorbed from the hydroxyl group. In comparison, the charge is reduced.
- the 4MU contained in the droplet of the hydrophilic solvent 42 has no electric charge or has a small electric charge, the 4MU easily moves to the hydrophobic solvent 43 that is in interface contact with the hydrophilic solvent 42. The organic solvent 42 is lost from the droplet, or the 4MU concentration in the droplet is lowered.
- the reaction between neuraminidase and 4MU-NANA is performed under pH conditions around 5 which is the optimum pH for the enzyme reaction by neuraminidase, and the detection of released 4MU is maximized with the fluorescence efficiency (quantum efficiency) of 4MU. It was carried out under a pH condition of around 10 which is a pH value.
- one of the technical features of the present invention is that the reaction of neuraminidase with 4MU-NANA and the detection of 4MU are both carried out under pH conditions higher than 4MU pKa7.79. is there.
- the reaction between the substrate 3 and the enzyme 5 can proceed if the substrate 3 and the enzyme 5 come into contact with each other even before this procedure.
- the hydrophilic solvent 42 containing the virus 2 and the substrate 3 is used.
- the generated reaction product 4 is not accumulated in the minimum volume. For this reason, in the optical detection of the reaction product 4, the influence of the reaction product 4 generated before the encapsulation procedure (2) is small enough to be ignored.
- reaction product 4 from the droplets of the hydrophilic solvent 42 to the hydrophobic solvent 43 covering the droplets similarly
- chromogenic substrates that can cause migration problems include:
- Derivatives containing 4-methylumbelliferone other than 4MU-NANA are derivatives containing 4-methylumbelliferone other than 4MU-NANA.
- the “derivative” means a compound having 4MU as “chromophore” and “substrate” cleaved by the reaction with the enzyme 5 in the structure.
- resorufin as a chromophore.
- the substrate When reacted with the enzyme 5, the substrate is cleaved by the enzyme 5 and resorufin (pKa: 6.0), which is a fluorescent substance, is released as the reaction product 4.
- resorufin pKa: 6.0
- the structure of resorufin is shown below.
- the pH value of the hydrophilic solvent 42 is set larger than the acid dissociation constant (pKa) of the reaction product 4 generated from the derivative. Thereby, each reaction product 4 is brought into a charged state, is prevented from shifting (leaking out) to the hydrophobic solvent 43, and the reaction product 4 is accumulated in a high concentration in the droplets of the hydrophilic solvent 42. (See Example 1).
- the concentration of the buffer substance is, for example, 50 mM or more, preferably 100 mM or more, more preferably 500 mM or more, and further preferably 1 M or more.
- the optical detection of the reaction product 4 can be performed using a known means capable of detecting a difference in optical properties between the substrate 3 and the reaction product 4. For example, by detecting a specific absorbance or optical rotation shift using an image sensor, an absorptiometer, or a polarimeter, and by detecting a specific fluorescence wavelength using an image sensor, a fluorescence microscope, or a fluorometer. Product 4 can be detected optically.
- the number of virus particles and / or subtypes can be determined.
- influenza virus first, the enzyme activity value of neuraminidase is calculated using the detected fluorescence intensity and a standard curve that defines the relationship between the fluorescence intensity and neuraminidase activity prepared in advance. Next, the number of influenza virus particles is quantified using the calculated enzyme activity value and a standard curve that defines the relationship between the enzyme activity value and the number of virus particles prepared in advance. In addition to determining whether the biological sample separated from the subject contains viruses, the amount of virus can also be determined quantitatively (analog quantification), and whether or not the subject is infected with influenza virus. Can be diagnosed. A standard curve that directly defines the relationship between the fluorescence intensity and the number of virus particles may be used.
- type A virus has higher neuraminidase activity than type B virus.
- the inventors of the present invention use the detection method according to the present invention that the type A virus and the type B virus differ by about twice in neuraminidase activity, and that both can be effectively distinguished and detected based on the magnitude of the activity value. Heading.
- the enzyme activity value of neuraminidase is calculated using the detected fluorescence intensity and a standard curve that defines the relationship between the fluorescence intensity and neuraminidase activity prepared in advance.
- the subtype of influenza virus can be determined using the calculated enzyme activity value and the relational expression between the enzyme activity value and the subtype prepared in advance.
- influenza virus it can be determined as type A if the calculated enzyme activity value is greater than or equal to the reference value, and can be determined as type B if it is less than the reference value.
- the virus subtype in addition to the determination of whether the virus is contained in the biological sample separated from the subject, the virus subtype can also be determined, and the subtype of the infected influenza virus in the subject can be diagnosed.
- a relational expression that directly defines the relationship between fluorescence intensity and subtype may be used.
- the number of viruses 2 entering one container 13 can be 0 or 1 at the maximum.
- the viral load can also be determined quantitatively (digital quantification) based on a defined standard curve.
- the reaction product 4 can be accumulated in a high concentration in the droplets of the hydrophilic solvent 42, so that even when only one particle of virus 2 is contained in the container 13.
- the reaction product 4 can be detected with high sensitivity. Therefore, according to the detection method of the present invention, even a very small amount of virus in a biological sample can be detected with high sensitivity, and the amount of pathogenic microorganisms can be determined with high accuracy.
- reaction product 4 can be accumulated in a high concentration in the droplets of the hydrophilic solvent 42 to obtain a high fluorescence intensity
- a simple imaging device with relatively low sensitivity can be used for optical detection.
- optical detection with a camera mounted on a smartphone is expected to be possible.
- Optical detection by a simple imaging device such as a camera mounted on a smartphone can facilitate the implementation of the pathogenic microorganism detection method according to the present invention in a relatively small hospital, clinic, or individual.
- the communication means provided in the smartphone is used, the detection information of pathogenic microorganisms is transmitted to the server, and the accumulated information (big data) is analyzed, so that it is possible to grasp the epidemic area, time, subtype, etc. It is expected to be available for prediction.
- the case where the virus 2 is an influenza virus and 4MU-NANA is used as the substrate 3 has been described as an example.
- the substrate 3 includes hemagglutinin esterase (on the surface) of these viruses. What is necessary is just to use what hydrolyzes by the enzyme 5) and releases the chromophore (reaction product 4) as mentioned above.
- the substrate 3 has reverse transcriptase (on the surface or inside thereof) It may be a nucleic acid monomer that is polymerized by the enzyme 5).
- the fluorescence intensity increased as compared with the nucleic acid monomer is detected in the nucleic acid chain that is a reaction product of polymerization.
- substrate 3 when the detection target is, for example, Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus or norovirus, substrate 3
- a fluorescent dye can be prepared by labeling a fluorescent dye to a nucleic acid monomer that is polymerized by the RNA-dependent RNA polymerase (enzyme 5) possessed on the surface or inside of these viruses.
- the substrate can be appropriately selected depending on the enzyme that is present on the surface or inside the pathogenic microorganism to be detected.
- the pH value of the hydrophilic solvent used in the introduction procedure (1) may be designed to be larger than the pKa according to the pKa of the selected reaction product.
- the substrate is a pathogenic microorganism having the same enzyme (neuraminidase) such as influenza virus and mump virus
- the substrate can be designed differently depending on the substrate specificity of the enzyme of each pathogenic microorganism.
- 4MU-NANA is used as a chromogenic substrate for detecting influenza virus
- a chromophore produced by hydrolysis of 4MU-NANA as a chromogenic substrate for detecting mump virus is converted from 4MU to other fluorescent substances such as fluorescein. Use what was changed to.
- the detection method according to the present invention can also detect both of them separately.
- the method for detecting drug sensitivity of a pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with the pathogenic microorganism according to the present invention is as follows. including. (B1) A plurality of accommodating portions capable of accommodating pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface where the accommodating portion in the lower layer portion is formed. In the space between the upper layers facing each other, a hydrophilic solvent containing the biological sample, a substance serving as a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism, and an inhibitor of the enzyme Installation procedure to be introduced.
- a hydrophobic solvent is introduced into the space, and droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substance, and the inhibitor are formed in the housing portion.
- Enclosure procedure to. (B3) a detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet, wherein the detection intensity of the reaction product in the presence of the inhibitor is , If it is less than the detected intensity of the reaction product in the absence of the inhibitor, it indicates that the pathogenic microorganism is sensitive to the inhibitor).
- the introduction procedure (B1) of the method for detecting drug susceptibility of pathogenic microorganisms according to the present invention is based on the above-described method for detecting pathogenic microorganisms only in that an enzyme inhibitor to be evaluated for drug sensitivity is contained in a hydrophilic solvent. Different from the introduction procedure (A1). In the introduction procedure (B1), in addition to the pathogenic microorganism and the substrate, an enzyme inhibitor present on the surface or inside of the pathogenic microorganism enters the container.
- Encapsulation procedure (B2) The operation of the encapsulation procedure (B2) of the method for detecting drug sensitivity of a pathogenic microorganism according to the present invention is the same as the encapsulation procedure (A2) of the above-mentioned pathogenic microorganism detection method.
- the encapsulation procedure (B2) droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substrate, and the inhibitor are formed in the container.
- Detection Procedure (B3) In the detection procedure (B3) of the method for detecting drug susceptibility of pathogenic microorganisms according to the present invention, the reaction generated in the droplet of the hydrophilic solvent in the same manner as the detection procedure (A3) of the above-described pathogenic microorganism detection method. Optical detection of the product is performed.
- the detection intensity of the reaction product in the presence of the inhibitor is compared with the detection intensity of the reaction product in the absence of the inhibitor, It is shown that the formation of reaction products in the droplets is suppressed. That is, the enzyme contained in the pathogenic microorganism is inhibited, which indicates that the pathogenic microorganism is sensitive to the inhibitor.
- the detection intensity of the reaction product in the absence of the inhibitor is equivalent to the detection intensity of the reaction product in the absence of the inhibitor
- the reaction in the droplet of the hydrophilic solvent Product formation is shown not to be inhibited by the inhibitor. That is, the enzyme contained in the pathogenic microorganism is not inhibited, indicating that the pathogenic microorganism is resistant to the inhibitor.
- the pathogenic microorganism is an influenza virus, for example, using 4MU-NANA as a substrate and neuraminidase inhibitors (such as osetamivir, zanamivir) as inhibitors
- neuraminidase inhibitors such as osetamivir, zanamivir
- the generated 4MU fluorescence is detected for the two test groups that are identical except under the following conditions.
- the detection intensity of 4MU in the presence of neuraminidase inhibitor is compared to the detection intensity of 4MU in the absence of neuraminidase inhibitor, if the former is reduced over the latter, the neuraminidase inhibitor will cause the It is shown that the generation of 4MU is suppressed.
- influenza virus is sensitive to neuraminidase inhibitors.
- the detection intensity of 4MU in the absence of neuraminidase inhibitor is comparable to the detection intensity of 4MU in the absence of neuraminidase inhibitor, the production of 4MU in the droplet of the hydrophilic solvent is neuraminidase. It is shown that it is not suppressed by the inhibitor. That is, the neuraminidase possessed by the influenza virus is not inhibited, indicating that the influenza virus is resistant to the neuraminidase inhibitor.
- HE hemagglutinin esterase
- HIV human immunodeficiency virus
- hepatitis B virus or human T cell leukemia virus HTLV
- inhibitors of reverse transcriptase retrovir ( GlaxoSmithKline Inc., Zidovudine / AZT), Videx (Bristol-Myers Squibb Inc., Zidanocin / ddI), Hibid (Hoffmanla Roche) (Zarcitabine / ddC), Zellit (Bristol-Myers Squibb), Stavudine / d4T), Epivir (GlaxoSmithKline, Lamivudine / 3TC) and Combivir (GlaxoSmithKline, Zidovudine / Lamivudine) Vilamune (Boehringer Ingelheim Pharmaceuticals Inc.
- retrovir GlaxoSmithKline Inc., Zidovudine / AZT
- Videx Bristol-Myers Squibb Inc., Zidanocin / d
- RNA-dependent RNA polymerase Fabipyravir, ribavirin, etc.
- Vibrio parahaemolyticus Vibrio parahaemolyticus, Campylobacter, Enterobacter or Bacillus spp. are targeted for detection, inhibitors of galactosidase (Castanospermine, Conduritol B Epoxide, Bromoconduritol, 2- etc.
- Deoxy-D-Galactose Deoxy-D-Galactose
- glucuronidase inhibitor Alsetoguraton, D-glucaro-1,4-lactone , lysophospholipids, etc.
- chymotrypsin trypsin inhibitor
- trypsin inhibitor Soybean, egg or the like derived trypsin inhibitor, Arg 4 - Examples include Met 5 -marinostatin, phenylmethylsulfonyl fluoride, aminoethyl benzylsulfonyl fluoride, Aprotinin, Tosyl lysine chloromethyl ketone, tosyl phenylalanine chloromethyl ketone, and inhibitors of xylosidase (Castanospermine, Xyl-amidine, etc.).
- the inhibitor in the method for detecting drug susceptibility of pathogenic microorganisms according to the present invention, can be appropriately selected depending on the enzyme present on the surface or inside the pathogenic microorganism to be detected.
- a method for screening an anti-pathogenic microbial drug according to the present invention includes the following procedures.
- a hydrophilic solvent containing the pathogenic microorganism, a substance serving as a substrate for a reaction by an enzyme existing on or inside the pathogenic microorganism, and a candidate compound is introduced into a space between the upper layers facing each other. Installation procedure to do.
- (C2) A hydrophobic solvent is introduced into the space, and droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substance, and the candidate compound are formed in the container. Enclosure procedure to. (C3) a detection procedure for optically detecting a reaction product generated by the reaction between the enzyme and the substance in the droplet, wherein the detection intensity of the reaction product in the presence of the candidate compound is , If it decreases below the detected intensity of the reaction product in the absence of the candidate compound, it indicates that the candidate compound has anti-pathogenic microbial activity).
- the introduction procedure (C1) of the screening method for an anti-pathogenic microbial agent according to the present invention is the above-mentioned pathogenic microorganism only in that a candidate compound to be evaluated for anti-pathogenic microbial activity is contained in a hydrophilic solvent. This is different from the detection method introduction procedure (A1). In the introduction procedure (C1), in addition to the pathogenic microorganism and the substrate, the candidate compound enters the housing unit.
- Encapsulation procedure (C2) The operation of the encapsulation procedure (C2) of the screening method for an anti-pathogenic microorganism according to the present invention is the same as the encapsulation procedure (A2) of the above-mentioned pathogenic microorganism detection method.
- the encapsulation procedure (C2) droplets of a hydrophilic solvent that are coated with a hydrophobic solvent and include pathogenic microorganisms, substrates, and candidate compounds are formed in the container.
- Detection Procedure (C3) In the detection procedure (C3) of the screening method for an anti-pathogenic microorganism according to the present invention, the reaction generated in the droplet of the hydrophilic solvent in the same manner as the detection procedure (A3) of the above-mentioned pathogenic microorganism detection method Optical detection of the product is performed.
- the detection intensity of the reaction product in the presence of the candidate compound is compared with the detection intensity of the reaction product in the absence of the candidate compound. It is shown that the formation of reaction products in the droplets is suppressed. That is, the enzyme possessed by the pathogenic microorganism is inhibited, indicating that the candidate compound has anti-pathogenic microbial activity.
- the detection intensity of the reaction product in the absence of the candidate compound is equivalent to the detection intensity of the reaction product in the absence of the candidate compound, the reaction in the droplet of the hydrophilic solvent Product formation is shown not to be inhibited by the inhibitor. That is, the enzyme possessed by the pathogenic microorganism is not inhibited, indicating that the candidate compound does not have anti-pathogenic microbial activity.
- Pathogenic microorganism detection kit is a kit for detecting pathogenic microorganisms in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism, A space between a lower layer portion in which a plurality of accommodating portions capable of accommodating the pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed An array comprising an upper layer portion facing each other, and A substance that is a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism particles; A hydrophilic solvent having a pH value greater than the acid dissociation constant (pKa) of the reaction product produced by the reaction between the enzyme and the substance; A hydrophobic solvent.
- pKa acid dissociation constant
- the kit according to the present invention includes the above-described array 1, the substrate 3, the hydrophilic solvent 42, and the hydrophobic solvent 43. Since the substrate 3, the hydrophilic solvent 42, and the hydrophobic solvent 43 are as described above, the configuration of the array 1 will be described in more detail below.
- the lower layer portion 10 of the array 1 includes a plate-like member 11 and a side wall 12 having a hydrophobic upper surface.
- a plurality of accommodating portions 13 are formed separated from each other by the side walls 12.
- the plate member 11 preferably has a hydrophilic surface. “Hydrophilic surface” refers to a surface that has a higher affinity with a hydrophilic solvent than with a hydrophobic solvent.
- the plate-like member 11 may be a solid material, but for example, glass, silicon, polymer resin, or the like can be used.
- the side wall 12 is a structure that separates each of the plurality of accommodating portions 13 provided on the surface of the plate-like member 11, preferably on the hydrophilic surface.
- the side wall 12 has a hydrophobic upper surface. “Hydrophobic” is used herein in the same meaning as “lipophilic” and means that the affinity with a hydrophobic solvent is higher than the affinity with a hydrophilic solvent.
- the side wall 12 only needs to have a hydrophobic upper surface, that is, a surface facing the upper layer portion 20, and the side surface, that is, the inner wall in the accommodating portion 13, may be hydrophobic or hydrophilic.
- the side wall 12 may be composed of a hydrophilic structure and a hydrophobic layer formed on the upper surface thereof.
- a hydrophilic structure for example, glass, silicon, polymer resin, or the like can be used.
- a hydrophobic layer for example, a water-repellent resin, a fluorine-based polymer resin, or the like can be used.
- the fluoropolymer resin include amorphous fluororesins. Amorphous fluororesin is preferably used because it has high hydrophobicity and low toxicity to biological samples.
- amorphous fluororesin for example, at least one selected from CYTOP (registered trademark), TEFLON (registered trademark) AF2400, and TEFLON (registered trademark) AF1600 can be suitably used.
- CYTOP registered trademark
- TEFLON registered trademark
- AF1600 TEFLON (registered trademark) AF1600
- CYTOP registered trademark
- TEFLON registered trademark
- the side wall 12 may be made of a hydrophobic material.
- a fluorine-based polymer resin for example, a paraxylylene-based polymer resin, or the like can be used.
- the fluoropolymer resin include amorphous fluororesins.
- the amorphous fluororesin the above-described resins can be suitably used.
- the side wall 12 should just be comprised so that the some accommodating part 13 may be formed on the plate-shaped member 11, for example, is a plate-shaped structure by which the hole is formed in the position in which the accommodating part 13 is formed. There may be.
- the housing portion 13 has a part of the surface of the plate-like member 11 as a bottom surface, and the bottom surface is hydrophilic.
- the shape of the region surrounded by the bottom surface and the side surface of the accommodating portion 13 may be, for example, a cylindrical shape, a prismatic shape, or the like.
- the bottom surface of the accommodating portion 13 is hydrophilic, and the top surface of the side wall 12 is hydrophobic.
- the upper layer portion 20 for example, glass, silicon, polymer resin, or the like can be used.
- the upper layer portion 20 faces the surface of the lower layer portion 10 on which the accommodating portion 13 is formed with a space 30 therebetween. That is, there is a space 30 between the side wall 12 and the hydrophobic layer 22. This space 30 constitutes a flow path. With this configuration, the array 1 has a flow cell structure.
- the space 30 can be used between the lower layer portion 10 and the upper layer portion 20 as a flow path for flowing a fluid in a direction parallel to the surfaces where the lower layer portion 10 and the upper layer portion 20 face each other.
- a through hole (not shown) for introducing a fluid into the space 30 may be formed in the lower layer portion 10 or the upper layer portion 20.
- the lower layer part 10 may have a region where the accommodating part 13 is formed and a region where the accommodating part 13 is not formed.
- the through-hole may be formed in the area
- the surface of the upper layer portion 20 constituting the upper surface of the space 30 is hydrophobic
- the lower surface of the space 30 is the hydrophobic upper surface of the side wall 12 and the accommodating portion 13. Therefore, all portions of the space 30 other than the bottom surface of the accommodating portion 13 are hydrophobic.
- the hydrophilic solvent 42 can be efficiently introduced into each accommodating portion 13.
- the hydrophobic solvent 43 is not allowed to enter the respective accommodating portions 13. Therefore, by introducing the hydrophobic solvent 43 into the space 30, it is possible to efficiently form droplets in the respective accommodating portions 13.
- a positive type photoresist (AZ-4903, AZ Electronic Materials) was spin-coated on the cover glass coated with the amorphous fluororesin and baked at 55 ° C. for 3 minutes, and further baked at 110 ° C. for 5 minutes. Photolithography was performed using a photomask having holes having a diameter of 3 ⁇ m at intervals of 5 ⁇ m. After dry etching with oxygen plasma, a washed cover glass was obtained as DAD. The DAD has a well (accommodating portion) having a diameter of 4 ⁇ m and a depth of 3 ⁇ m (about 1 million pieces / 10 mm 2 ), and the cover glass is exposed on the bottom surface of the well. An array having a flow cell structure as shown in FIG. 1 was prepared using the obtained DAD.
- 4-MU was dissolved in a buffer solution (33 mM DEA-HCl, 4 mM CaCl 2 ) adjusted to pH 6.5 to 9.0 to 50 ⁇ M.
- 30 ⁇ L of a buffer solution in which 4-MU was dissolved was introduced into the array, and each well was filled with the buffer solution (see FIG. 1A).
- 200 ⁇ L of a hydrophobic solvent (FC40) was introduced into the array, and droplets of the hydrophilic solvent coated with the hydrophobic solvent were formed in each well.
- a fluorescence image of each droplet was taken with a CMOS camera (NeosCMOS, Andor) connected to a fluorescence microscope (IX8, OLYMPUS), and the fluorescence intensity was measured.
- Photographing was performed by dividing an area of 10 mm 2 for each well into 120 parts. One image includes about 8,600 wells. The fluorescence image was analyzed with image analysis software (Meta-Morph, Molecular Devices), and the fluorescence intensity was calculated.
- 4-MU was dissolved in a buffer solution (4 mM CaCl 2 , pH 6.5) adjusted to a DEA concentration of 25 mM to 1 M to a concentration of 50 ⁇ M.
- 30 ⁇ L of a buffer solution in which 4-MU was dissolved was introduced into the array, and each well was filled with the buffer solution (see FIG. 1A).
- 200 ⁇ L of a hydrophobic solvent (FC40) was introduced into the array, and droplets of the hydrophilic solvent coated with the hydrophobic solvent were formed in each well.
- Time-lapse photography was performed under a fluorescence microscope, and the fluorescence intensity of each droplet was measured.
- the fluorescence of 4MU can be detected with higher sensitivity by setting the concentration of the buffer substance in the buffer solution to 50 mM or more. Indicated. It is considered that the migration (leakage) of 4MU FC40 could be suppressed by setting the buffer substance in the buffer solution to a predetermined concentration or more.
Abstract
Description
[1] 病原性微生物に感染した対象又は感染した疑いがある対象から分離された生物試料中の前記病原性微生物を検出する方法であって、
前記病原性微生物を収容可能な複数の収容部が、疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における当該収容部が形成されている面に対向している上層部との間の空間に、前記生物試料と、前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、を含む親水性溶媒を導入する導入手順と、
前記空間に疎水性溶媒を導入して、前記収容部内に、疎水性溶媒で被覆されかつ前記病原性微生物と前記物質を包含する、親水性溶媒の液滴を形成する封入手順と、
前記液滴中における前記酵素と前記物質との反応により生成する反応生成物を光学的に検出する検出手順と、を含み、
前記親水性溶媒が、前記反応生成物の酸解離定数(pKa)よりも大きいpH値を有する、方法。
[2] 前記反応生成物の検出強度に基づいて前記病原性微生物の数及び/又は亜種を決定する手順をさらに含む、[1]の方法。
[3] 前記病原性微生物がインフルエンザウイルスであり、前記酵素がノイラミニダーゼであり、前記物質が4-メチルウンベリフェリル-α-D-ノイラミン酸(4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid)であり、前記反応生成物が4-メチルウンベリフェロンである、[1]又は[2]の方法。
[4] 前記病原性微生物がコロナウイルス、重症急性呼吸器症候群(SARS)コロナウイルス、中東呼吸器症候群(MERS)ウイルス、ムンプウイルス、麻疹ウイルス、ニパウイルス、イヌジステンパーウイルス、ヒト免疫不全ウイルス(HIV)、B型肝炎ウイルス、ヒトT細胞白血病ウイルス(HTLV)、エボラウイルス、C型肝炎ウイルス、ラッサウイルス、ハンタウイルス、狂犬病ウイルス、日本脳炎ウイルス、黄熱ウイルス、デング熱ウイルス、風疹ウイルス、ロタウイルス及びノロウイルスからなる群より選択される一以上であり、前記酵素がヘマグルチニンエステラーゼ、ノイラミニダーゼ、逆転写酵素及びRNA依存RNAポリメラーゼからなる群より選択される一以上である、[1]又は[2]の方法。
[5] 前記物質が4-メチルウンベリフェロン(4-Methylumbelliferone)を含む誘導体、フルオレセイン(Fluorescein)を含む誘導体、レゾルフィン(Resorufin)を含む誘導体及びローダミン(Rhodamine)を含む誘導体からなる群より選択される一以上である、[1]又は[2]の方法。 In order to solve the above problems, the present invention provides the following [1] to [25].
[1] A method for detecting the pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism,
A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed. An introduction procedure for introducing a hydrophilic solvent containing the biological sample and a substance serving as a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism into a space between the upper layer portion,
An encapsulation procedure for introducing a hydrophobic solvent into the space, and forming droplets of the hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism and the substance in the container,
A detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet,
The method, wherein the hydrophilic solvent has a pH value greater than the acid dissociation constant (pKa) of the reaction product.
[2] The method according to [1], further comprising a step of determining the number and / or subspecies of the pathogenic microorganisms based on the detected intensity of the reaction product.
[3] The pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl-α-D-neuraminic acid (4-Methylumbelliferyl-N-acetyl-α-D-neuraminic). acid), and the reaction product is 4-methylumbelliferone [1] or [2].
[4] The pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [1] or [2], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase and RNA-dependent RNA polymerase.
[5] The substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine. [1] or [2].
感染した疑いがある対象から生物試料を分離する手順と、
前記病原性微生物を収容可能な複数の収容部が、疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における当該収容部が形成されている面に対向している上層部との間の空間に、前記生物試料と、前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、を含む親水性溶媒を導入する導入手順と、
前記空間に疎水性溶媒を導入して、前記収容部内に、疎水性溶媒で被覆されかつ前記病原性微生物と前記物質とを包含する、親水性溶媒の液滴を形成する封入手順と、
前記液滴中における前記酵素と前記物質との反応により生成する反応生成物を光学的に検出する検出手順、(ここで、前記反応生成物の検出は、前記病原性微生物の感染を示す)と、
を含む、方法。
[7] 前記親水性溶媒が、前記反応生成物の酸解離定数(pKa)よりも大きいpH値を有する、[6]の方法。
[8] 前記反応生成物の検出強度に基づいて病原性微生物の数及び/又は亜種を決定する手順をさらに含む、[6]又は[7]の方法。
[9] 前記病原性微生物がインフルエンザウイルスであり、前記酵素がノイラミニダーゼであり、前記物質が4-メチルウンベリフェリル-α-D-ノイラミン酸(4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid)であり、前記反応生成物が4-メチルウンベリフェロンである、[6]~[8]のいずれかの方法。
[10] 前記病原性微生物がコロナウイルス、重症急性呼吸器症候群(SARS)コロナウイルス、中東呼吸器症候群(MERS)ウイルス、ムンプウイルス、麻疹ウイルス、ニパウイルス、イヌジステンパーウイルス、ヒト免疫不全ウイルス(HIV)、B型肝炎ウイルス、ヒトT細胞白血病ウイルス(HTLV)、エボラウイルス、C型肝炎ウイルス、ラッサウイルス、ハンタウイルス、狂犬病ウイルス、日本脳炎ウイルス、黄熱ウイルス、デング熱ウイルス、風疹ウイルス、ロタウイルス及びノロウイルスからなる群より選択される一以上であり、前記酵素がヘマグルチニンエステラーゼ、ノイラミニダーゼ、逆転写酵素及びRNA依存RNAポリメラーゼからなる群より選択される一以上である、[6]~[8]のいずれかの方法。
[11] 前記物質が4-メチルウンベリフェロン(4-Methylumbelliferone)を含む誘導体、フルオレセイン(Fluorescein)を含む誘導体、レゾルフィン(Resorufin)を含む誘導体及びローダミン(Rhodamine)を含む誘導体からなる群より選択される一以上である、[6]~[8]のいずれかの方法。 [6] A method for diagnosing the presence or absence of infection with a pathogenic microorganism,
A procedure for separating a biological sample from a subject suspected of being infected;
A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed. An introduction procedure for introducing a hydrophilic solvent containing the biological sample and a substance serving as a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism into a space between the upper layer portion,
An encapsulation procedure for introducing a hydrophobic solvent into the space, and forming droplets of the hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism and the substance in the accommodating portion;
A detection procedure for optically detecting a reaction product produced by a reaction between the enzyme and the substance in the droplet, wherein the detection of the reaction product indicates infection of the pathogenic microorganism; ,
Including a method.
[7] The method according to [6], wherein the hydrophilic solvent has a pH value larger than the acid dissociation constant (pKa) of the reaction product.
[8] The method according to [6] or [7], further comprising a step of determining the number and / or subspecies of pathogenic microorganisms based on the detected intensity of the reaction product.
[9] The pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl-α-D-neuraminic acid (4-Methylumbelliferyl-N-acetyl-α-D-neuraminic). acid) and the reaction product is 4-methylumbelliferone, [6] to [8].
[10] The pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus Any one of [6] to [8], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase, and RNA-dependent RNA polymerase. Method.
[11] The substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine. Any one of [6] to [8].
前記病原性微生物を収容可能な複数の収容部が、疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における当該収容部が形成されている面に対向している上層部との間の空間に、前記生物試料と、前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、前記酵素の阻害薬を含む親水性溶媒を導入する導入手順と、
前記空間に疎水性溶媒を導入して、前記収容部内に、疎水性溶媒で被覆されかつ前記病原性微生物と前記物質と前記阻害薬とを包含する、親水性溶媒の液滴を形成する封入手順と、
前記液滴中における前記酵素と前記物質との反応により生成する反応生成物を光学的に検出する検出手順、(ここで、前記阻害薬の存在下における前記反応生成物の検出強度が、前記阻害薬の非存在下における前記反応生成物の検出強度よりも減少する場合、前記病原性微生物が前記阻害薬に感受性を有することを示す)と、
を含む、方法。
[13] 前記親水性溶媒が、前記反応生成物の酸解離定数(pKa)よりも大きいpH値を有する、[12]の方法。
[14] 前記病原性微生物がインフルエンザウイルスであり、前記酵素がノイラミニダーゼであり、前記物質が4-メチルウンベリフェリル-α-D-ノイラミン酸(4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid)であり、前記反応生成物が4-メチルウンベリフェロンであり、前記阻害薬がノイラミニダーゼ阻害薬である、[12]又は[13]の方法。 [12] A method for detecting drug sensitivity of a pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism,
A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed. A hydrophilic solvent containing the biological sample, a substance serving as a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism, and an inhibitor of the enzyme; Introduction procedure and
An enclosing procedure for introducing a hydrophobic solvent into the space to form a droplet of a hydrophilic solvent that is coated with the hydrophobic solvent and includes the pathogenic microorganism, the substance, and the inhibitor in the container. When,
A detection procedure for optically detecting a reaction product produced by a reaction between the enzyme and the substance in the droplet, wherein the detection intensity of the reaction product in the presence of the inhibitor is the inhibition Indicating that the pathogenic microorganism is sensitive to the inhibitor if it decreases below the detected intensity of the reaction product in the absence of a drug),
Including a method.
[13] The method according to [12], wherein the hydrophilic solvent has a pH value larger than an acid dissociation constant (pKa) of the reaction product.
[14] The pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl-α-D-neuraminic acid (4-Methylumbelliferyl-N-acetyl-α-D-neuraminic). acid), the reaction product is 4-methylumbelliferone, and the inhibitor is a neuraminidase inhibitor [12] or [13].
病原性微生物を収容可能な複数の収容部が、疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における当該収容部が形成されている面に対向している上層部との間の空間に、前記病原性微生物と、前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、候補化合物とを含む親水性溶媒を導入する導入手順と、
前記空間に疎水性溶媒を導入して、前記収容部内に、疎水性溶媒で被覆されかつ前記病原性微生物と前記物質と前記候補化合物とを包含する、親水性溶媒の液滴を形成する封入手順と、
前記液滴中における前記酵素と前記物質との反応により生成する反応生成物を光学的に検出する検出手順、(ここで、前記候補化合物の存在下における前記反応生成物の検出強度が、前記候補化合物の非存在下における前記反応生成物の検出強度よりも減少する場合、前記候補化合物が抗病原性微生物活性を有することを示す)と、
を含む、方法。
[16] 前記親水性溶媒が、前記反応生成物の酸解離定数(pKa)よりも大きいpH値を有する、[15]の方法。
[17] 前記病原性微生物がインフルエンザウイルスであり、前記酵素がノイラミニダーゼであり、前記物質が4-メチルウンベリフェリル-α-D-ノイラミン酸(4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid)であり、前記反応生成物が4-メチルウンベリフェロンであり、前記候補化合物としてノイラミニダーゼ阻害薬がスクリーニングされる、[15]又は[16]の方法。 [15] A method of screening for anti-pathogenic microbial agents,
A plurality of accommodating parts capable of accommodating pathogenic microorganisms are opposed to a lower layer part formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface on which the accommodating part is formed in the lower layer part Introducing a hydrophilic solvent containing the pathogenic microorganism, a substance serving as a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism, and a candidate compound into a space between the upper layer portion and the upper layer portion When,
An enclosing procedure for introducing a hydrophobic solvent into the space and forming droplets of a hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism, the substance, and the candidate compound in the container. When,
A detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet, wherein the detection intensity of the reaction product in the presence of the candidate compound is the candidate Indicates that the candidate compound has anti-pathogenic microbial activity if it decreases below the detected intensity of the reaction product in the absence of the compound);
Including a method.
[16] The method according to [15], wherein the hydrophilic solvent has a pH value larger than an acid dissociation constant (pKa) of the reaction product.
[17] The pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl-α-D-neuraminic acid (4-Methylumbelliferyl-N-acetyl-α-D-neuraminic). acid), the reaction product is 4-methylumbelliferone, and a neuraminidase inhibitor is screened as the candidate compound [15] or [16].
前記病原性微生物を収容可能な複数の収容部が疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、前記下層部における前記収容部が形成されている面に対して空間を隔てて対向している上層部とを備えるアレイと、
前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、
前記酵素と前記物質との反応により生成する反応生成物の酸解離定数(pKa)よりも大きいpH値を有する親水性溶媒と、
疎水性溶媒と、を含むキット。
[19] 前記病原性微生物がインフルエンザウイルスであり、前記酵素がノイラミニダーゼであり、前記物質が4-メチルウンベリフェリル-α-D-ノイラミン酸(4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid)であり、前記反応生成物が4-メチルウンベリフェロンである、[18]のキット。
[20] 前記病原性微生物がコロナウイルス、重症急性呼吸器症候群(SARS)コロナウイルス、中東呼吸器症候群(MERS)ウイルス、ムンプウイルス、麻疹ウイルス、ニパウイルス、イヌジステンパーウイルス、ヒト免疫不全ウイルス(HIV)、B型肝炎ウイルス、ヒトT細胞白血病ウイルス(HTLV)、エボラウイルス、C型肝炎ウイルス、ラッサウイルス、ハンタウイルス、狂犬病ウイルス、日本脳炎ウイルス、黄熱ウイルス、デング熱ウイルス、風疹ウイルス、ロタウイルス及びノロウイルスからなる群より選択される一以上であり、前記酵素がヘマグルチニンエステラーゼ、ノイラミニダーゼ、逆転写酵素及びRNA依存RNAポリメラーゼからなる群より選択される一以上である、[18]のキット。
[21] 前記物質が4-メチルウンベリフェロン(4-Methylumbelliferone)を含む誘導体、フルオレセイン(Fluorescein)を含む誘導体、レゾルフィン(Resorufin)を含む誘導体及びローダミン(Rhodamine)を含む誘導体からなる群より選択される一以上である、[18]のキット。 [18] A kit for detecting the pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism,
A space between a lower layer portion in which a plurality of accommodating portions capable of accommodating the pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed An array comprising an upper layer portion facing each other, and
A substance that is a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism;
A hydrophilic solvent having a pH value greater than the acid dissociation constant (pKa) of the reaction product produced by the reaction between the enzyme and the substance;
A kit comprising a hydrophobic solvent.
[19] The pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl-α-D-neuraminic acid (4-Methylumbelliferyl-N-acetyl-α-D-neuraminic). acid), and the reaction product is 4-methylumbelliferone [18].
[20] The pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, Middle East respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [18] The kit according to [18], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase, and RNA-dependent RNA polymerase.
[21] The substance is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine. The kit according to [18], which is one or more.
前記親水性溶媒が、前記反応生成物の酸解離定数(pKa)よりも大きいpH値を有する、方法。
[23] 前記親水性溶媒が病原性微生物を含み、
前記酵素が前記病原性微生物の表面又は内部に存在する基質切断活性を有する酵素であり、
前記物質が発色基質であり、
前記酵素による前記発色基質の切断により生成する反応生成物を光学的に検出する、[22]の方法。
[24] 前記病原性微生物がインフルエンザウイルスであり、前記酵素がノイラミニダーゼであり、前記発色基質が4-メチルウンベリフェリル-α-D-ノイラミン酸(4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid)であり、前記反応生成物が4-メチルウンベリフェロンである、[23]の方法。
[25] 前記病原性微生物がコロナウイルス、重症急性呼吸器症候群(SARS)コロナウイルス、中東呼吸器症候群(MERS)ウイルス、ムンプウイルス、麻疹ウイルス、ニパウイルス、イヌジステンパーウイルス、ヒト免疫不全ウイルス(HIV)、B型肝炎ウイルス、ヒトT細胞白血病ウイルス(HTLV)、エボラウイルス、C型肝炎ウイルス、ラッサウイルス、ハンタウイルス、狂犬病ウイルス、日本脳炎ウイルス、黄熱ウイルス、デング熱ウイルス、風疹ウイルス、ロタウイルス及びノロウイルスからなる群より選択される一以上であり、前記酵素がヘマグルチニンエステラーゼ、ノイラミニダーゼ、逆転写酵素及びRNA依存RNAポリメラーゼからなる群より選択される一以上である、[23]の方法。
[26] 前記発色基質が4-メチルウンベリフェロン(4-Methylumbelliferone)を含む誘導体、フルオレセイン(Fluorescein)を含む誘導体、レゾルフィン(Resorufin)を含む誘導体及びローダミン(Rhodamine)を含む誘導体からなる群より選択される一以上である、[23]の方法。
[27] 前記親水性溶媒が、前記病原性微生物に感染した対象又は感染した疑いがある対象から分離された生物試料を含む、[23]~[26]のいずれかの方法。 [22] A method of detecting a reaction product by reacting an enzyme with a substance serving as a substrate for a reaction by the enzyme in a hydrophilic solvent in interface with the hydrophobic solvent,
The method, wherein the hydrophilic solvent has a pH value greater than the acid dissociation constant (pKa) of the reaction product.
[23] The hydrophilic solvent contains a pathogenic microorganism,
The enzyme is an enzyme having a substrate cleavage activity present on the surface or inside of the pathogenic microorganism,
The substance is a chromogenic substrate;
[22] The method according to [22], wherein a reaction product generated by cleavage of the chromogenic substrate by the enzyme is optically detected.
[24] The pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the chromogenic substrate is 4-methylumbelliferyl-α-D-neuraminic acid (4-Methylumbelliferyl-N-acetyl-α-D- The method according to [23], wherein the reaction product is 4-methylumbelliferone.
[25] The pathogenic microorganism is coronavirus, severe acute respiratory syndrome (SARS) coronavirus, middle east respiratory syndrome (MERS) virus, mump virus, measles virus, nipavirus, canine distemper virus, human immunodeficiency virus (HIV), From hepatitis B virus, human T cell leukemia virus (HTLV), Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus and norovirus [23] The method according to [23], wherein the enzyme is one or more selected from the group consisting of hemagglutinin esterase, neuraminidase, reverse transcriptase and RNA-dependent RNA polymerase.
[26] The chromogenic substrate is selected from the group consisting of a derivative containing 4-methylumbelliferone, a derivative containing fluorescein, a derivative containing resorufin, and a derivative containing rhodamine. The method of [23], which is one or more of the following.
[27] The method of any of [23] to [26], wherein the hydrophilic solvent comprises a biological sample separated from a subject infected with or suspected of being infected with the pathogenic microorganism.
本発明に係る病原性微生物検出方法は、病原性微生物に感染した対象又は感染した疑いがある対象から分離された生物試料中の病原性微生物を検出するために用いられるものである。本発明に係る病原性微生物検出方法は、以下の手順を含む。
(1A)病原性微生物を収容可能な複数の収容部が、疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における当該収容部が形成されている面に対向している上層部との間の空間に、前記生物試料と、前記病原性微生物の粒子表面又は内部に存在する酵素による反応の基質となる物質と、を含む親水性溶媒を導入する導入手順。
(2A)前記空間に疎水性溶媒を導入して、前記収容部内に、疎水性溶媒で被覆されかつ前記病原性微生物と前記物質を包含する、親水性溶媒の液滴を形成する封入手順。
(3A)前記液滴中における前記酵素と前記物質との反応により生成する反応生成物を光学的に検出する検出手順。 1. Pathogenic microorganism detection method The pathogenic microorganism detection method according to the present invention is used to detect pathogenic microorganisms in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism. is there. The pathogenic microorganism detection method according to the present invention includes the following procedures.
(1A) On the surface where the plurality of accommodating portions capable of accommodating pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and the surface where the accommodating portion in the lower layer portion is formed An introduction procedure for introducing a hydrophilic solvent containing the biological sample and a substance serving as a substrate for a reaction by an enzyme present on the surface of or inside the particle of the pathogenic microorganism into a space between the upper layers facing each other. .
(2A) An encapsulation procedure in which a hydrophobic solvent is introduced into the space to form a droplet of a hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism and the substance in the container.
(3A) A detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet.
図1Aを参照して導入手順(A1)を説明する。本実施形態では、病原性微生物(以下、ウイルスを例に説明する)を収容可能な複数の収容部が疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における前記収容部が形成されている面に対して空間を隔てて対向している上層部とを備えるアレイを用いて、本発明に係る病原性微生物検出方法を実施する場合について説明する。 [Introduction procedure (A1)]
The introduction procedure (A1) will be described with reference to FIG. 1A. In the present embodiment, a lower layer part in which a plurality of accommodating parts capable of accommodating pathogenic microorganisms (hereinafter described as an example of a virus) are separated from each other by a side wall having a hydrophobic upper surface, and the lower layer part The case where the pathogenic microorganism detection method according to the present invention is carried out using an array including an upper layer part facing the surface on which the housing part is formed with a space therebetween will be described.
図1Bを参照して封入手順(2)を説明する。本手順では、下層部10と上層部20との間の空間30に疎水性溶媒43を導入する。 [Encapsulation procedure (A2)]
The encapsulation procedure (2) will be described with reference to FIG. 1B. In this procedure, the hydrophobic solvent 43 is introduced into the
本手順では、親水性溶媒42の液滴中に生成した反応生成物4の光学検出を行う。 [Detection Procedure (A3)]
In this procedure, optical detection of the
封入手順(2)においては、親水性溶媒42の液滴中に反応生成物4を高濃度に蓄積させることができるため、ウイルス2が1粒子のみ収容部13に入っている場合であっても、反応生成物4の検出を高感度に行うことができる。従って、本発明に係る検出方法によれば、生物試料中にごく微量に含まれるウイルスであっても高感度に検出でき、病原性微生物の量を高精度に決定することが可能となる。 Furthermore, as described above, when the
In the encapsulation procedure (2), the
本発明に係る病原性微生物に感染した対象又は感染した疑いがある対象から分離された生物試料中の病原性微生物の薬剤感受性を検出する方法は、以下の手順を含む。
(B1)病原性微生物を収容可能な複数の収容部が、疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における当該収容部が形成されている面に対向している上層部との間の空間に、前記生物試料と、前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、前記酵素の阻害薬を含む親水性溶媒を導入する導入手順。
(B2)前記空間に疎水性溶媒を導入して、前記収容部内に、疎水性溶媒で被覆されかつ前記病原性微生物と前記物質と前記阻害薬とを包含する、親水性溶媒の液滴を形成する封入手順。
(B3)前記液滴中における前記酵素と前記物質との反応により生成する反応生成物を光学的に検出する検出手順、(ここで、前記阻害薬の存在下における前記反応生成物の検出強度が、前記阻害薬の非存在下における前記反応生成物の検出強度よりも減少する場合、前記病原性微生物が前記阻害薬に感受性を有することを示す)。 2. Method for Detecting Drug Sensitivity of Pathogenic Microorganism The method for detecting drug sensitivity of a pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with the pathogenic microorganism according to the present invention is as follows. including.
(B1) A plurality of accommodating portions capable of accommodating pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface where the accommodating portion in the lower layer portion is formed. In the space between the upper layers facing each other, a hydrophilic solvent containing the biological sample, a substance serving as a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism, and an inhibitor of the enzyme Installation procedure to be introduced.
(B2) A hydrophobic solvent is introduced into the space, and droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substance, and the inhibitor are formed in the housing portion. Enclosure procedure to.
(B3) a detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet, wherein the detection intensity of the reaction product in the presence of the inhibitor is , If it is less than the detected intensity of the reaction product in the absence of the inhibitor, it indicates that the pathogenic microorganism is sensitive to the inhibitor).
本発明に係る病原性微生物の薬剤感受性の検出方法の導入手順(B1)は、薬剤感受性の評価対象となる酵素阻害薬が親水性溶媒に含まれる点でのみ、上述の病原性微生物検出方法の導入手順(A1)と異なる。導入手順(B1)では、病原性微生物及び基質に加えて、病原性微生物の表面又は内部に存在する酵素の阻害薬が収容部に入ることとなる。 [Introduction procedure (B1)]
The introduction procedure (B1) of the method for detecting drug susceptibility of pathogenic microorganisms according to the present invention is based on the above-described method for detecting pathogenic microorganisms only in that an enzyme inhibitor to be evaluated for drug sensitivity is contained in a hydrophilic solvent. Different from the introduction procedure (A1). In the introduction procedure (B1), in addition to the pathogenic microorganism and the substrate, an enzyme inhibitor present on the surface or inside of the pathogenic microorganism enters the container.
本発明に係る病原性微生物の薬剤感受性の検出方法の封入手順(B2)の操作は、上述の病原性微生物検出方法の封入手順(A2)に同じである。封入手順(B2)では、収容部内に、疎水性溶媒で被覆されかつ病原性微生物、基質及び阻害薬を包含する、親水性溶媒の液滴が形成されることとなる。 [Encapsulation procedure (B2)]
The operation of the encapsulation procedure (B2) of the method for detecting drug sensitivity of a pathogenic microorganism according to the present invention is the same as the encapsulation procedure (A2) of the above-mentioned pathogenic microorganism detection method. In the encapsulation procedure (B2), droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substrate, and the inhibitor are formed in the container.
本発明に係る病原性微生物の薬剤感受性の検出方法の検出手順(B3)では、上述の病原性微生物検出方法の検出手順(A3)と同様にして、親水性溶媒の液滴中に生成した反応生成物の光学検出を行う。 [Detection Procedure (B3)]
In the detection procedure (B3) of the method for detecting drug susceptibility of pathogenic microorganisms according to the present invention, the reaction generated in the droplet of the hydrophilic solvent in the same manner as the detection procedure (A3) of the above-described pathogenic microorganism detection method. Optical detection of the product is performed.
一方、阻害薬の非存在下における前記反応生成物の検出強度が、阻害薬の非存在下における前記反応生成物の検出強度と比較して同等である場合、親水性溶媒の液滴中における反応生成物の生成は阻害剤によって抑制されていないことが示される。すなわち、病原性微生物が有する酵素は阻害されていないことから、病原性微生物が阻害薬に耐性を有することが示される。 When the detection intensity of the reaction product in the presence of the inhibitor is compared with the detection intensity of the reaction product in the absence of the inhibitor, It is shown that the formation of reaction products in the droplets is suppressed. That is, the enzyme contained in the pathogenic microorganism is inhibited, which indicates that the pathogenic microorganism is sensitive to the inhibitor.
On the other hand, when the detection intensity of the reaction product in the absence of the inhibitor is equivalent to the detection intensity of the reaction product in the absence of the inhibitor, the reaction in the droplet of the hydrophilic solvent Product formation is shown not to be inhibited by the inhibitor. That is, the enzyme contained in the pathogenic microorganism is not inhibited, indicating that the pathogenic microorganism is resistant to the inhibitor.
一方、ノイラミニダーゼ阻害剤の非存在下における4MUの検出強度が、ノイラミニダーゼ阻害剤の非存在下における4MUの検出強度と比較して同等である場合、親水性溶媒の液滴中における4MUの生成はノイラミニダーゼ阻害剤によって抑制されていないことが示される。すなわち、インフルエンザウイルスが有するノイラミニダーゼは阻害されていないことから、インフルエンザウイルスがノイラミニダーゼ阻害剤に耐性を有することが示される。 Specifically, when the pathogenic microorganism is an influenza virus, for example, using 4MU-NANA as a substrate and neuraminidase inhibitors (such as osetamivir, zanamivir) as inhibitors, the presence or absence of neuraminidase inhibitors The generated 4MU fluorescence is detected for the two test groups that are identical except under the following conditions. When the detection intensity of 4MU in the presence of neuraminidase inhibitor is compared to the detection intensity of 4MU in the absence of neuraminidase inhibitor, if the former is reduced over the latter, the neuraminidase inhibitor will cause the It is shown that the generation of 4MU is suppressed. That is, since neuraminidase possessed by influenza virus is inhibited, it is shown that influenza virus is sensitive to neuraminidase inhibitors.
On the other hand, when the detection intensity of 4MU in the absence of neuraminidase inhibitor is comparable to the detection intensity of 4MU in the absence of neuraminidase inhibitor, the production of 4MU in the droplet of the hydrophilic solvent is neuraminidase. It is shown that it is not suppressed by the inhibitor. That is, the neuraminidase possessed by the influenza virus is not inhibited, indicating that the influenza virus is resistant to the neuraminidase inhibitor.
同様に、例えば、エボラウイルス、C型肝炎ウイルス、ラッサウイルス、ハンタウイルス、狂犬病ウイルス、日本脳炎ウイルス、黄熱ウイルス、デング熱ウイルス、風疹ウイルス、ロタウイルスあるいはノロウイルスを検出対象とする場合、これらのウイルスが表面又は内部に有するRNA依存RNAポリメラーゼの阻害薬(ファビピラビル、リバビリン等)が挙げられる。 In addition, for example, when human immunodeficiency virus (HIV), hepatitis B virus or human T cell leukemia virus (HTLV) is to be detected, inhibitors of reverse transcriptase (retrovir ( GlaxoSmithKline Inc., Zidovudine / AZT), Videx (Bristol-Myers Squibb Inc., Zidanocin / ddI), Hibid (Hoffmanla Roche) (Zarcitabine / ddC), Zellit (Bristol-Myers Squibb), Stavudine / d4T), Epivir (GlaxoSmithKline, Lamivudine / 3TC) and Combivir (GlaxoSmithKline, Zidovudine / Lamivudine) Vilamune (Boehringer Ingelheim Pharmaceuticals Inc. , Nevirapine), Rescriptor (Pharmacia / Upjohn, delavirdine), and SUSTIVA (DuPont Pharma · Co., efavirenz), and the like).
Similarly, for example, when detecting Ebola virus, hepatitis C virus, Lassa virus, hantavirus, rabies virus, Japanese encephalitis virus, yellow fever virus, dengue virus, rubella virus, rotavirus or norovirus, these viruses Inhibitors of RNA-dependent RNA polymerase (Fabipyravir, ribavirin, etc.) possessed on the surface or inside.
本発明に係る抗病原性微生物薬剤をスクリーニングする方法は、以下の手順を含む。
(C1)病原性微生物を収容可能な複数の収容部が、疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における当該収容部が形成されている面に対向している上層部との間の空間に、前記病原性微生物と、前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、候補化合物とを含む親水性溶媒を導入する導入手順。
(C2)前記空間に疎水性溶媒を導入して、前記収容部内に、疎水性溶媒で被覆されかつ前記病原性微生物と前記物質と前記候補化合物とを包含する、親水性溶媒の液滴を形成する封入手順。
(C3)前記液滴中における前記酵素と前記物質との反応により生成する反応生成物を光学的に検出する検出手順、(ここで、前記候補化合物の存在下における前記反応生成物の検出強度が、前記候補化合物の非存在下における前記反応生成物の検出強度よりも減少する場合、前記候補化合物が抗病原性微生物活性を有することを示す)。 3. Screening Method for Anti-Pathogenic Microbial Drug A method for screening an anti-pathogenic microbial drug according to the present invention includes the following procedures.
(C1) On the surface where the plurality of accommodating portions capable of accommodating pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and on the surface where the accommodating portion in the lower layer portion is formed A hydrophilic solvent containing the pathogenic microorganism, a substance serving as a substrate for a reaction by an enzyme existing on or inside the pathogenic microorganism, and a candidate compound is introduced into a space between the upper layers facing each other. Installation procedure to do.
(C2) A hydrophobic solvent is introduced into the space, and droplets of the hydrophilic solvent that are covered with the hydrophobic solvent and include the pathogenic microorganism, the substance, and the candidate compound are formed in the container. Enclosure procedure to.
(C3) a detection procedure for optically detecting a reaction product generated by the reaction between the enzyme and the substance in the droplet, wherein the detection intensity of the reaction product in the presence of the candidate compound is , If it decreases below the detected intensity of the reaction product in the absence of the candidate compound, it indicates that the candidate compound has anti-pathogenic microbial activity).
本発明に係る抗病原性微生物薬剤のスクリーニング方法の導入手順(C1)は、抗病原性微生物活性の評価対象となる候補化合物が親水性溶媒に含まれる点でのみ、上述の病原性微生物検出方法の導入手順(A1)と異なる。導入手順(C1)では、病原性微生物及び基質に加えて、候補化合物が収容部に入ることとなる。 [Introduction procedure (C1)]
The introduction procedure (C1) of the screening method for an anti-pathogenic microbial agent according to the present invention is the above-mentioned pathogenic microorganism only in that a candidate compound to be evaluated for anti-pathogenic microbial activity is contained in a hydrophilic solvent. This is different from the detection method introduction procedure (A1). In the introduction procedure (C1), in addition to the pathogenic microorganism and the substrate, the candidate compound enters the housing unit.
本発明に係る抗病原性微生物薬剤のスクリーニング方法の封入手順(C2)の操作は、上述の病原性微生物検出方法の封入手順(A2)に同じである。封入手順(C2)では、収容部内に、疎水性溶媒で被覆されかつ病原性微生物、基質及び候補化合物を包含する、親水性溶媒の液滴が形成される。 [Encapsulation procedure (C2)]
The operation of the encapsulation procedure (C2) of the screening method for an anti-pathogenic microorganism according to the present invention is the same as the encapsulation procedure (A2) of the above-mentioned pathogenic microorganism detection method. In the encapsulation procedure (C2), droplets of a hydrophilic solvent that are coated with a hydrophobic solvent and include pathogenic microorganisms, substrates, and candidate compounds are formed in the container.
本発明に係る抗病原性微生物薬剤のスクリーニング方法の検出手順(C3)では、上述の病原性微生物検出方法の検出手順(A3)と同様にして、親水性溶媒の液滴中に生成した反応生成物の光学検出を行う。 [Detection Procedure (C3)]
In the detection procedure (C3) of the screening method for an anti-pathogenic microorganism according to the present invention, the reaction generated in the droplet of the hydrophilic solvent in the same manner as the detection procedure (A3) of the above-mentioned pathogenic microorganism detection method Optical detection of the product is performed.
一方、候補化合物の非存在下における前記反応生成物の検出強度が、候補化合物の非存在下における前記反応生成物の検出強度と比較して同等である場合、親水性溶媒の液滴中における反応生成物の生成は阻害剤によって抑制されていないことが示される。すなわち、病原性微生物が有する酵素は阻害されていないことから、候補化合物が抗病原性微生物活性を有しないことが示される。 The detection intensity of the reaction product in the presence of the candidate compound is compared with the detection intensity of the reaction product in the absence of the candidate compound. It is shown that the formation of reaction products in the droplets is suppressed. That is, the enzyme possessed by the pathogenic microorganism is inhibited, indicating that the candidate compound has anti-pathogenic microbial activity.
On the other hand, when the detection intensity of the reaction product in the absence of the candidate compound is equivalent to the detection intensity of the reaction product in the absence of the candidate compound, the reaction in the droplet of the hydrophilic solvent Product formation is shown not to be inhibited by the inhibitor. That is, the enzyme possessed by the pathogenic microorganism is not inhibited, indicating that the candidate compound does not have anti-pathogenic microbial activity.
本発明に係るキットは、病原性微生物に感染した対象又は感染した疑いがある対象から分離された生物試料中の病原性微生物を検出するためのキットであって、
前記病原性微生物を収容可能な複数の収容部が疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、前記下層部における前記収容部が形成されている面に対して空間を隔てて対向している上層部とを備えるアレイと、
前記病原性微生物の粒子表面又は内部に存在する酵素による反応の基質となる物質と、
前記酵素と前記物質との反応により生成する反応生成物の酸解離定数(pKa)よりも大きいpH値を有する親水性溶媒と、
疎水性溶媒と、を含む。 4). Pathogenic microorganism detection kit The kit according to the present invention is a kit for detecting pathogenic microorganisms in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism,
A space between a lower layer portion in which a plurality of accommodating portions capable of accommodating the pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed An array comprising an upper layer portion facing each other, and
A substance that is a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism particles;
A hydrophilic solvent having a pH value greater than the acid dissociation constant (pKa) of the reaction product produced by the reaction between the enzyme and the substance;
A hydrophobic solvent.
以下の手順によって、親水性溶媒のpH値が検出感度に及ぼす影響を検討した。
まず、金らの報告(" Quantifying genetically inserted fluorescent protein in single iPS cells to monitor Nanog expression using electroactive microchamber arrays", Lab on Chip, 2014, Issue 4, Vol.14, p.730-736)に従って、Droplet array device(DAD)を作成した。カバーガラス(24mm×32mm)を洗浄、乾燥した後、アモルファスフッ素樹脂(CYTOP 816AP、旭硝子)をスピンコートし、180℃で1時間焼成した。アモルファスフッ素樹脂がコートされたカバーガラスに、ポジ型フォトレジスト(AZ-4903、AZ Electronic Materials)をスピンコートして、55℃で3分間焼成した後、さらに110℃で5分間焼成した。直径3μmの穴を5μm間隔で有するフォトマスクを用いてフォトリソグラフィーを行った。酸素プラズマでドライエッチング後、洗浄したカバーガラスをDADとして得た。DADは、直径4μm、深さ3μmのウェル(収容部)を有し(約100万個/10mm2)、ウェルの底面はカバーガラスが露出している。得られたDADを用いて図1に示すようなフローセル構造のアレイを作成した。 [Test Example 1: Examination of pH value of hydrophilic solvent]
The influence of the pH value of the hydrophilic solvent on the detection sensitivity was examined by the following procedure.
First, according to Kim et al.'S report ("Quantifying genetically inserted fluorescent protein in single iPS cells to monitor Nanog expression using electroactive microchamber arrays", Lab on Chip, 2014,
4-MUを溶解したバッファー溶液30μLをアレイに導入し各ウェルにバッファー溶液を充填した(図1A参照)。続いて、アレイに疎水性溶媒(FC40)を200μL導入し、各ウェルに疎水性溶媒で被覆された親水性溶媒の液滴を形成させた。
蛍光顕微鏡(IX8, OLYMPUS)に接続されたCMOSカメラ(Neo sCMOS, Andor)で、各液滴の蛍光画像を撮影し、蛍光強度を測定した。各ウェルにつき10mm2の領域を120分割して撮影を行った。1枚の画像には約8,600個のウェルが含まれる。蛍光画像を画像解析ソフト(Meta-Morph, Molecular Devices)で解析し、蛍光強度を算出した。 4-MU was dissolved in a buffer solution (33 mM DEA-HCl, 4 mM CaCl 2 ) adjusted to pH 6.5 to 9.0 to 50 μM.
30 μL of a buffer solution in which 4-MU was dissolved was introduced into the array, and each well was filled with the buffer solution (see FIG. 1A). Subsequently, 200 μL of a hydrophobic solvent (FC40) was introduced into the array, and droplets of the hydrophilic solvent coated with the hydrophobic solvent were formed in each well.
A fluorescence image of each droplet was taken with a CMOS camera (NeosCMOS, Andor) connected to a fluorescence microscope (IX8, OLYMPUS), and the fluorescence intensity was measured. Photographing was performed by dividing an area of 10 mm 2 for each well into 120 parts. One image includes about 8,600 wells. The fluorescence image was analyzed with image analysis software (Meta-Morph, Molecular Devices), and the fluorescence intensity was calculated.
以下の手順によって、親水性溶媒の緩衝物質濃度が検出感度に及ぼす影響を検討した。 [Test Example 2: Examination of buffer substance concentration of hydrophilic solvent]
The influence of the buffer substance concentration of the hydrophilic solvent on the detection sensitivity was examined by the following procedure.
4-MUを溶解したバッファー溶液30μLをアレイに導入し各ウェルにバッファー溶液を充填した(図1A参照)。続いて、アレイに疎水性溶媒(FC40)を200μL導入し、各ウェルに疎水性溶媒で被覆された親水性溶媒の液滴を形成させた。
蛍光顕微鏡下でタイムラプス撮影を行い、各液滴の蛍光強度を測定した。 4-MU was dissolved in a buffer solution (4 mM CaCl 2 , pH 6.5) adjusted to a DEA concentration of 25 mM to 1 M to a concentration of 50 μM.
30 μL of a buffer solution in which 4-MU was dissolved was introduced into the array, and each well was filled with the buffer solution (see FIG. 1A). Subsequently, 200 μL of a hydrophobic solvent (FC40) was introduced into the array, and droplets of the hydrophilic solvent coated with the hydrophobic solvent were formed in each well.
Time-lapse photography was performed under a fluorescence microscope, and the fluorescence intensity of each droplet was measured.
Claims (7)
- 病原性微生物に感染した対象又は感染した疑いがある対象から分離された生物試料中の前記病原性微生物を検出する方法であって、
前記病原性微生物を収容可能な複数の収容部が、疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、当該下層部における当該収容部が形成されている面に対向している上層部との間の空間に、前記生物試料と、前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、を含む親水性溶媒を導入する導入手順と、
前記空間に疎水性溶媒を導入して、前記収容部内に、疎水性溶媒で被覆されかつ前記病原性微生物と前記物質を包含する、親水性溶媒の液滴を形成する封入手順と、
前記液滴中における前記酵素と前記物質との反応により生成する反応生成物を光学的に検出する検出手順と、を含み、
前記親水性溶媒が、前記反応生成物の酸解離定数(pKa)よりも大きいpH値を有する、方法。 A method for detecting the pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of being infected with a pathogenic microorganism,
A plurality of accommodating portions capable of accommodating the pathogenic microorganisms are opposed to a lower layer portion formed by being separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed. An introduction procedure for introducing a hydrophilic solvent containing the biological sample and a substance serving as a substrate for a reaction by an enzyme present on the surface or inside of the pathogenic microorganism into a space between the upper layer portion,
An encapsulation procedure for introducing a hydrophobic solvent into the space, and forming droplets of the hydrophilic solvent that is covered with the hydrophobic solvent and includes the pathogenic microorganism and the substance in the container,
A detection procedure for optically detecting a reaction product generated by a reaction between the enzyme and the substance in the droplet,
The method, wherein the hydrophilic solvent has a pH value greater than the acid dissociation constant (pKa) of the reaction product. - 前記病原性微生物がインフルエンザウイルスであり、前記酵素がノイラミニダーゼであり、前記物質が4-メチルウンベリフェリル-α-D-ノイラミン酸(4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid)であり、前記反応生成物が4-メチルウンベリフェロンである、請求項1記載の方法。 The pathogenic microorganism is influenza virus, the enzyme is neuraminidase, and the substance is 4-methylumbelliferyl-α-D-neuraminic acid The method of claim 1, wherein the reaction product is 4-methylumbelliferone.
- 病原性微生物に感染した対象又は感染した疑いがある対象から分離された生物試料中の前記病原性微生物を検出するためのキットであって、
前記病原性微生物を収容可能な複数の収容部が疎水性の上面を有する側壁によって互いに隔てられて形成されている下層部と、前記下層部における前記収容部が形成されている面に対して空間を隔てて対向している上層部とを備えるアレイと、
前記病原性微生物の表面又は内部に存在する酵素による反応の基質となる物質と、
前記酵素と前記物質との反応により生成する反応生成物の酸解離定数(pKa)よりも大きいpH値を有する親水性溶媒と、
疎水性溶媒と、を含むキット。 A kit for detecting the pathogenic microorganism in a biological sample isolated from a subject infected with or suspected of having the pathogenic microorganism,
A space between a lower layer portion in which a plurality of accommodating portions capable of accommodating the pathogenic microorganisms are separated from each other by a side wall having a hydrophobic upper surface, and a surface of the lower layer portion where the accommodating portion is formed An array comprising an upper layer portion facing each other, and
A substance that is a substrate for a reaction by an enzyme present on or inside the pathogenic microorganism;
A hydrophilic solvent having a pH value greater than the acid dissociation constant (pKa) of the reaction product produced by the reaction between the enzyme and the substance;
A kit comprising a hydrophobic solvent. - 疎水性溶媒と界面接触する親水性溶媒中において、酵素と、該酵素による反応の基質となる物質とを反応させ、反応生成物を検出する方法であって、
前記親水性溶媒が、前記反応生成物の酸解離定数(pKa)よりも大きいpH値を有する、方法。 A method of detecting a reaction product by reacting an enzyme with a substance that is a substrate for a reaction by the enzyme in a hydrophilic solvent that is in interface contact with the hydrophobic solvent,
The method, wherein the hydrophilic solvent has a pH value greater than the acid dissociation constant (pKa) of the reaction product. - 前記親水性溶媒が病原性微生物を含み、
前記酵素が前記病原性微生物の表面又は内部に存在する基質切断活性を有する酵素であり、
前記物質が発色基質であり、
前記酵素による前記発色基質の切断により生成する反応生成物を光学的に検出する、請求項4記載の方法。 The hydrophilic solvent comprises pathogenic microorganisms;
The enzyme is an enzyme having a substrate cleavage activity present on the surface or inside of the pathogenic microorganism,
The substance is a chromogenic substrate;
The method according to claim 4, wherein a reaction product produced by cleavage of the chromogenic substrate by the enzyme is optically detected. - 前記病原性微生物がインフルエンザウイルスであり、前記酵素がノイラミニダーゼであり、前記発色基質が4-メチルウンベリフェリル-α-D-ノイラミン酸(4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid)であり、前記反応生成物が4-メチルウンベリフェロンである、請求項5記載の方法。 The pathogenic microorganism is an influenza virus, the enzyme is neuraminidase, and the chromogenic substrate is 4-methylumbelliferyl-α-D-neuraminic acid (4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid) 6. The method of claim 5, wherein the reaction product is 4-methylumbelliferone.
- 前記親水性溶媒が、前記病原性微生物に感染した対象又は感染した疑いがある対象から分離された生物試料を含む、請求項5又は6記載の方法。
7. The method of claim 5 or 6, wherein the hydrophilic solvent comprises a biological sample isolated from a subject infected with or suspected of being infected with the pathogenic microorganism.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/329,829 US11008603B2 (en) | 2016-09-05 | 2017-09-04 | Method and kit for detecting pathogenic microorganism |
CN201780054148.5A CN109689882A (en) | 2016-09-05 | 2017-09-04 | Method and kit for pathogenic microbes detection |
EP17846736.1A EP3508586A4 (en) | 2016-09-05 | 2017-09-04 | Method and kit for detecting pathogenic microorganism |
BR112019004272A BR112019004272A2 (en) | 2016-09-05 | 2017-09-04 | method and kit for detecting pathogenic microorganism |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016-172515 | 2016-09-05 | ||
JP2016172515 | 2016-09-05 | ||
JP2017-099579 | 2017-05-19 | ||
JP2017099579A JP7016136B2 (en) | 2016-09-05 | 2017-05-19 | Methods and kits for detecting pathogenic microorganisms |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018043733A1 true WO2018043733A1 (en) | 2018-03-08 |
Family
ID=61301218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/031689 WO2018043733A1 (en) | 2016-09-05 | 2017-09-04 | Method and kit for detecting pathogenic microorganism |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7274780B2 (en) |
WO (1) | WO2018043733A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019168200A1 (en) * | 2018-03-02 | 2019-09-06 | 国立研究開発法人科学技術振興機構 | Method for detecting enzymatic reaction product |
WO2020179858A1 (en) * | 2019-03-05 | 2020-09-10 | 国立研究開発法人科学技術振興機構 | Method and kit for detecting influenza virus, and method for diagnosing influenza virus infection |
US11008603B2 (en) | 2016-09-05 | 2021-05-18 | Japan Science And Technology Agency | Method and kit for detecting pathogenic microorganism |
CN113825830A (en) * | 2019-05-20 | 2021-12-21 | 日本航空电子工业株式会社 | Electrochemical detection method and sensor for catalytic reaction product |
WO2022025044A1 (en) * | 2020-07-29 | 2022-02-03 | 京セラ株式会社 | Flow path device |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60252464A (en) * | 1984-04-06 | 1985-12-13 | クルト・ヴアレンフエルス | Substrates for hydrolase and manufacture |
JP2002541858A (en) | 1999-04-16 | 2002-12-10 | ザイメテックス インコーポレイテッド | Virus detection method using virus-derived enzyme and chemiluminescent substrate |
JP2003506455A (en) * | 1999-08-05 | 2003-02-18 | スリーエム イノベイティブ プロパティズ カンパニー | Fluorescent compounds and uses thereof |
JP2006500940A (en) * | 2002-10-01 | 2006-01-12 | メティス バイオテクノロジーズ | Method for detecting and counting microorganisms in a sample |
JP2008275511A (en) | 2007-05-01 | 2008-11-13 | Bl:Kk | Method for measuring immunity of influenza virus antigen and device used for the same |
JP2011139656A (en) | 2010-01-06 | 2011-07-21 | Osaka Gas Co Ltd | Method and apparatus for detecting influenza virus |
JP2013101110A (en) * | 2011-10-21 | 2013-05-23 | Hitachi High-Technologies Corp | Liquid chromatograph and analysis method |
JP2015034809A (en) * | 2013-07-10 | 2015-02-19 | 国立大学法人 東京大学 | Fluorescence lifetime imaging probe |
WO2016006208A1 (en) * | 2014-07-08 | 2016-01-14 | 国立研究開発法人科学技術振興機構 | Substance sealing method and target molecule detecting method |
-
2017
- 2017-09-04 WO PCT/JP2017/031689 patent/WO2018043733A1/en active Application Filing
-
2021
- 2021-11-22 JP JP2021189073A patent/JP7274780B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60252464A (en) * | 1984-04-06 | 1985-12-13 | クルト・ヴアレンフエルス | Substrates for hydrolase and manufacture |
JP2002541858A (en) | 1999-04-16 | 2002-12-10 | ザイメテックス インコーポレイテッド | Virus detection method using virus-derived enzyme and chemiluminescent substrate |
JP2003506455A (en) * | 1999-08-05 | 2003-02-18 | スリーエム イノベイティブ プロパティズ カンパニー | Fluorescent compounds and uses thereof |
JP2006500940A (en) * | 2002-10-01 | 2006-01-12 | メティス バイオテクノロジーズ | Method for detecting and counting microorganisms in a sample |
JP2008275511A (en) | 2007-05-01 | 2008-11-13 | Bl:Kk | Method for measuring immunity of influenza virus antigen and device used for the same |
JP2011139656A (en) | 2010-01-06 | 2011-07-21 | Osaka Gas Co Ltd | Method and apparatus for detecting influenza virus |
JP2013101110A (en) * | 2011-10-21 | 2013-05-23 | Hitachi High-Technologies Corp | Liquid chromatograph and analysis method |
JP2015034809A (en) * | 2013-07-10 | 2015-02-19 | 国立大学法人 東京大学 | Fluorescence lifetime imaging probe |
WO2016006208A1 (en) * | 2014-07-08 | 2016-01-14 | 国立研究開発法人科学技術振興機構 | Substance sealing method and target molecule detecting method |
Non-Patent Citations (7)
Title |
---|
"Quantifying genetically inserted fluorescent protein in single iPS cells to monitor Nanog expression using electroactive microchamber arrays", LAB ON CHIP, vol. 14, no. 4, 2014, pages 730 - 736 |
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 9002-93-1 |
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 9005-64-5 |
KIM, S.H. ET AL.: "Quantifying genetically inserted fluorescent protein in single iPS cells to monitor Nanog expression using electroactive microchamber arrays", LAB ON A CHIP, vol. 14, 2014, pages 730 - 736, XP055579586 * |
ROWLAND, B. ET AL.: "Fluorescence-based detection of lacZ reporter gene expression in intact and viable bacteria including Mycobacterium species", FEMS MICROBIOLOGY LETTERS, vol. 179, no. 2, 15 October 1999 (1999-10-15), pages 317 - 325, XP002320081, DOI: doi:10.1111/j.1574-6968.1999.tb08744.x * |
S. SAKAKIHARA ET AL., LAB CHIP, vol. 10, 2010, pages 3355 - 3362 |
ZHANG, F. ET AL.: "A simple and rapid fluorescent meuraminidase enzymatic assay on a microfluidic chip", DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol. 74, no. 3, 2012, pages 263 - 266, XP028948608, DOI: doi:10.1016/j.diagmicrobio.2012.07.011 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11008603B2 (en) | 2016-09-05 | 2021-05-18 | Japan Science And Technology Agency | Method and kit for detecting pathogenic microorganism |
WO2019168200A1 (en) * | 2018-03-02 | 2019-09-06 | 国立研究開発法人科学技術振興機構 | Method for detecting enzymatic reaction product |
WO2020179858A1 (en) * | 2019-03-05 | 2020-09-10 | 国立研究開発法人科学技術振興機構 | Method and kit for detecting influenza virus, and method for diagnosing influenza virus infection |
EP3936618A4 (en) * | 2019-03-05 | 2023-01-25 | Japan Science and Technology Agency | Method and kit for detecting influenza virus, and method for diagnosing influenza virus infection |
CN113825830A (en) * | 2019-05-20 | 2021-12-21 | 日本航空电子工业株式会社 | Electrochemical detection method and sensor for catalytic reaction product |
WO2022025044A1 (en) * | 2020-07-29 | 2022-02-03 | 京セラ株式会社 | Flow path device |
Also Published As
Publication number | Publication date |
---|---|
JP2022031760A (en) | 2022-02-22 |
JP7274780B2 (en) | 2023-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7016136B2 (en) | Methods and kits for detecting pathogenic microorganisms | |
JP7274780B2 (en) | Methods and kits for detection of pathogenic microorganisms | |
JP6477940B2 (en) | Biomolecule analysis method and biomolecule analysis kit | |
AU2012308326B2 (en) | Molecular diagnostic assay device and method of use | |
Obayashi et al. | A single-molecule digital enzyme assay using alkaline phosphatase with a cumarin-based fluorogenic substrate | |
JP2023520754A (en) | Rapid, field-deployable detection of the SARS-CoV-2 virus | |
US20120004141A1 (en) | Amplified bioassay | |
WO2019168200A1 (en) | Method for detecting enzymatic reaction product | |
WO2007141030A2 (en) | A method for the detection of enzymatic reactions | |
Cló et al. | Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis | |
JP4253695B2 (en) | Substance determination method and substance determination device | |
EP3974844A1 (en) | Method for detecting target molecule | |
Honda et al. | Multidimensional digital bioassay platform based on an air-sealed femtoliter reactor array device | |
WO2019098301A1 (en) | Target molecule detection method | |
JP4519794B2 (en) | Microchannel element | |
Stromberg et al. | Membrane insertion for the detection of lipopolysaccharides: Exploring the dynamics of amphiphile-in-lipid assays | |
US10018627B2 (en) | Method for sealing substances, method for detecting target molecule, array, kit, and target molecule detection device | |
Zhang et al. | Neuraminidase-activatable NIR fluorescent probe for influenza virus ratiometric imaging in living cells and colorimetric detection on cotton swabs | |
Zhang et al. | A simple and rapid fluorescent neuraminidase enzymatic assay on a microfluidic chip | |
US20220145407A1 (en) | Method and kit for detecting influenza virus, and method for diagnosing influenza virus infection | |
Ortiz et al. | Bleed‐to‐read disposable microsystems for the genetic and serological analysis of celiac disease markers with amperometric detection | |
Saito et al. | Liposome Flotation Assay for Studying Interactions Between Rubella Virus Particles and Lipid Membranes | |
US20220088598A1 (en) | Method of introducing liquid into wells | |
Tan et al. | UPDATE ON RAPID DIAGNOSTIC TESTING FOR COVID-19: Received 2021-09-09; Accepted 2021-10-08; Published 2021-10-26 | |
WO2000073800A1 (en) | Method for assaying anti-gad antibody and kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17846736 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017846736 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019004272 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112019004272 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190301 |